经内镜LAK／IL－2治疗消化道肿瘤

本文使用白细胞介素Ⅱ（ＩＬ─２）和淋巴因子激活的杀伤细胞（ＬＡＫ细胞）联合经内镜和全身注射免疫治疗８例晚期消化道恶性肿瘤。每例病人予ＩＬ─２５×１０３Ｕ～２×１０５Ｕ，肌注１／日，内镜下及静脉滴注ＬＡＫ细胞交替进行，每次ＬＡＫ细胞１×１０８～２×１０９，１次／２日。ＬＡＫ细胞治疗一般疗程５次，ＩＬ─２疗程２０天。结果表明，局部病灶ＣＲ１例，ＰＲ５例，ＭＲ１例，ＮＲ１例。     

细胞因子对树突状细胞抗肝癌作用的影响

目的研究人血树突状细胞（ＤＣ）和细胞因子ＴＮＦ,ＧＭＣＳＦ或ＩＦＮγ联合ＤＣ对淋巴因子和ＰＨＡ激活的杀伤细胞（ＬＰＡＫ细胞）体外杀伤人肝癌细胞株ＢＥＬ７４０２的影响．方法实验分为Ｌ组（ＬＰＡＫ）,Ｄ组（ＬＰＡＫ＋ＤＣ）,Ｔ１组（ＬＰＡＫ＋ＤＣ＋ＴＮＦ５０００ｋＵ／Ｌ）,Ｔ２组（ＬＰＡＫ＋ＤＣ＋ＴＮＦ５００ｋＵ／Ｌ）,Ｇ１组（ＬＰＡＫ＋ＤＣ＋ＧＭ－ＣＳＦ５００ｋＵ／Ｌ）,Ｇ２组（ＬＰＡＫ＋ＤＣ＋ＧＭ－ＣＳＦ１００ｋＵ／Ｌ）,Ｉ１组（ＬＰＡＫ＋ＤＣ＋ＩＦＮγ５００ｋＵ／Ｌ）和Ｉ２组（ＬＰＡＫ＋ＤＣ＋ＩＦＮγ１００ｋＵ／Ｌ）．每组效靶细胞比分别采用５∶１和１０∶１两种．培养４８ｈ后用中性红比色法检测细胞毒活性．结果Ｌ,Ｄ,Ｔ２和Ｔ１组的细胞毒活性依次增强,各组间差异有显著性（Ｐ＜００１）．Ｇ１和Ｇ２组均高于Ｄ组（Ｐ＜００１）,但Ｇ１,Ｇ２组间差异无显著性．Ｉ１,Ｉ２组与Ｄ组相比,也无显著性差异．随效靶比增加,各组细胞毒活性均相应增强．结论ＤＣ能增强ＬＰＡＫ细胞对肝癌细胞ＢＥＬ７４０２的细胞毒活性;ＴＮＦ或ＧＭＣＳＦ与ＤＣ联用,两者有协同作用;但与ＩＦＮγ联用,则无进一步增强作用     

CD3AK细胞联合IL—2脂质体抗鼠肝转移瘤的实验研究

目的 观察ＩＬ－２脂质体对ＣＤ３ＡＫ体内抗肿瘤的增强作用。方法：利用Ｇ５７ＢＬ／６小鼠脾细胞与抗ＣＤ３单克隆抗体和白细胞介素－－－２（ＩＬ－２）共同培养制备ＣＤ３ＡＫ细胞（ＣＤ３ＭｃＡｂ ａｃｔｉｖａｔｅｃｄ ｋｉｌｌｅｒ ｃｅｌｌｓ）；从脾内注射Ｂ１６黑色素瘤细胞制备鼠肝转移瘤模型：用ＰＣ和ＣＨ合成ＩＬ－２复合脂质体；ＣＤ３ＡＫ细胞联合ＩＬ－２脂质体用于体内抗Ｂ１６黑色素瘤肝转移。结果：共同培养     

哮喘患者辅助T细胞活化与白细胞介素5释放

目的 了解过敏状态和哮喘状态下辅助（ＣＤ４＾＋）Ｔ细胞活化及白细胞介素５（ＩＬ－５）释放的原因和作用。方法 对过敏性哮喘组１２例（ＡＡ）、非过敏性哮喘组１０例（ＮＡＡ）、过敏性非哮喘组９例（ＡＮ）及正常对照组１０名（Ｎ）在有无抗原刺激下进行支气管肺泡灌洗液（ＢＡＬＦ）细胞及周围血单个核细胞（ＰＢＭＣ）培养，比较组内和组间ＣＤ４＾＋Ｔ细胞活化（标志物ＣＤ２５＾＋）与ＩＬ－５释放水平。结果 ＰＢＭＣ在     

病毒性肝炎和肝硬化患者IL－6、TNF－α的变化

为研究白细胞介素－６（ＩＬ－６）、肿瘤坏死因子（ＴＮＦ－α）在肝炎和肝硬化（ＬＣ）患者中的作用。检测了１５例正常人，１８例急性病毒性肝炎（ＡＨ），３７例慢性肝炎（ＣＨ），２０例ＬＣ患者血清及外周血单个核细胞（ＰＢＭＣ）的ＩＬ－６、ＴＮＦ－α水平。结果以ＣＨ患者ＩＬ－６、ＴＮＦ－α水平最高（血清及ＰＢＭＣ的ＩＬ－６水平分别为７２．１±３２．９４Ｕ／ｍｌ，１４０．７±３３．５Ｕ／ｍｌ；血清及ＰＢＭＣ的ＴＮＦ－α水平为３．９７±１．３８ｎｇ／ｍｌ，６．３５±１．４１ｎｇ／ｍｌ）。恢复期或稳定期ＴＮＦ－α和ＩＬ－６水平明显低于急性期或活动期（Ｐ＜０．０１）。ＣＨ患者肝组织学活动指数（ＨＡＩ）分数与ＰＢＭＣＩＬ－６和ＴＮＦ－α水平呈正相关（γ分别为０．８９，０．６８；Ｐ＜０．０５）。提示ＩＬ－６和ＴＮＦ－α是肝脏损害重要的炎症介质，介导肝细胞损害。     

地塞米松对哮喘患者IL—4,IL—5及IgE合成的抑制作用观察

观察了地塞米松（Ｄｅｘ）对哮喘患考外周血单个核细胞（ＰＢＭＣ）合成白介素－４（ＩＬ－４）、白介素－５（ＩＬ－５）和免疫球蛋白Ｅ（ＩｇＥ）的抑制作用。结果证明，哮喘１组（仅用植物血凝素，简称ＰＨＡ）ＰＢＭＣ合成ＩＬ－４、ＩＬ－５、ＩｇＥ较对照组（仅用ＰＨＡ）明显增高（Ｐ＜０．０１），哮喘２组（ＰＨＡ＋Ｄｅｘ）ＰＢＭＣ合成ＩＬ－４、ＩＬ－５、ＩｇＥ较哮喘１组显著下降（Ｐ＜０．０５）。认为Ｄｅｘ治疗哮喘的机理，部分是通过减少ＩＬ－４ＩＬ－５、ＩｇＥ的合成而达到抗炎的目的。     

间质性肺疾病支气管肺泡灌洗液的酶活性研究

目的探讨支气管肺泡灌洗液（ＢＡＬＦ）多项酶活性与间质性肺疾病（ＩＬＤ）的关系。方法检测３０例ＩＬＤｓ：包括特发性肺纤维化（ＩＰＦ）１８例和结节病（Ｓａｒｃ）１２例与９例正常对照者的ＢＡＬＦ中超氧化歧化酶（ＳＯＤ）、谷胱甘肽过氧化物酶（ＧＳＨ－ＰＸ）、血管紧张素转换酶（ＡＣＥ）和乳酸脱氢酶（ＬＤＨ）活性，并分类计数ＢＡＬＦ细胞成份。结果（１）ＩＰＦ组ＢＡＬＦ中各项酶活性均与对照组间差异有显著性（ＳＯＤ和ＧＳＨ－ＰＸ降低，ＡＣＥ和ＬＤＨ升高）（Ｐ＜０．０５）；而Ｓａｒｃ组仅见ＡＣＥ明显增高（Ｐ＜０．０５）。（２）ＢＡＬＦ－ＡＣＥ与Ｓａｒｃ组淋巴细胞百分比及ＣＤ＋４／ＣＤ＋８比值均有显著线性相关（Ｐ＜０．０５）。结论ＢＡＬＦ中ＳＯＤ、ＧＳＨ－ＰＸ、ＡＣＥ和ＬＤＨ活性测定，有助于进一步探讨ＩＬＤ发病机理和提供辅助诊断依据，ＢＡＬＦ－ＡＣＥ对判断Ｓａｒｃ活动性有重要临床意义。     

LAK细胞治疗慢性乙,丙型肝炎疗效及免疫机制研究

报道应用自体ＬＡＫ细胞回输治疗１１０例慢性乙型肝炎（乙肝）和２０例慢性丙型肝炎（丙肝）的结果。疗程结束时慢性乙肝治疗组ＨＢｅＡｇ阴转率、抗－ＨＢｅ阳转率和ＨＢｖＤＮＡ阴转率分别为４６，４％、３５．５％和４８．２％，与对照组相比明显提高（Ｐ均〈０．００５）；２ｏ例慢性丙肝经治疗后抗－ＨＣＶ阴转２例（１０％），ＨＣＶＲＮＡ阴转４例（２０％），而对照组维持不变。进而对ＬＡＫ治疗的免疫机制进行探讨，结果发现ＬＡＫ治疗后ＣＡＨ患者ＣＤ＋４阳性率、ＣＤ＋４／ｃＤ＋８比值均增高（Ｐ＜０．０５），外周血单个核细胞膜白细胞介素－２受体（ｍＩＬ－２Ｒ）和血清中可溶性白细胞介素－２受体（ｓＩＬ－２Ｒ）的水平也明显升高（Ｐ＜０．０１）。     

IL-1与IL-2联合激活的骨髓对白血病细胞的净化作用

目的：体外观察白细胞介素－１（ＩＬ－１）对白细胞介素－２（ＩＬ－２）激活骨髓自然杀伤细胞（ＮＫ）和淋巴因子－激活杀伤细胞（ＬＡＫ）活性的影响及两者联合激活的骨髓对白血病细胞的净化作用。方法：标准４ｈ＾５１Ｃｒ释放实验测定激活骨髓的细胞毒作用;集落培养法观察激活骨髓对ＨＬ－６０和Ｋ５６２细胞的净化作用。结果：１０～２００μｇ／ＬＩＬ－１对正常骨髓的ＮＫ和ＬＡＫ活性无明显影响;ＩＬ－２能够增强骨髓的ＮＫ活性和诱导ＬＡＫ细胞的产生,呈浓度递增趋势;１００μｇ／ＬＩＬ－１能增强１万～１００万Ｕ／ＬＩＬ－２诱导的骨髓ＮＫ及ＬＡＫ活性。在体外净化实验中,１００μｇ／Ｌ ＩＬ－１或１００万Ｕ／Ｌ ＩＬ－２对Ｋ５６２和（或）ＨＬ－６０细胞无直接杀伤,而在掺入１％Ｋ５６２或ＨＬ－６０的正常骨髓中,加入ＩＬ－１和（或）ＩＬ－２,对     

40例慢性乙型肝炎后肝硬化的LAK细胞回输治疗

４０例慢性乙型肝炎后肝硬化的ＬＡＫ细胞回输治疗申淑兰，李玉彬，陈乃玲我们选用小剂量基因工程ＩＬ－２（北京希波公司提供），与患者静脉血ＰＢＭＣ在体外短时孵育后的自体ＬＡＫ细胞回输，配合对症治疗慢性乙型肝炎后肝硬化４０例，使部分患者ＨＢｅＡｇ和ＨＢＶ－Ｄ...     

Effects of lymphokine-activated killer cells and interleukin-2 on the ascites formation and the survival time of nude mice bearing human ovarian cancer cells

Summary The effect of intraperitoneal instillations of interleukin-2 (IL-2) and/or lympokine-activated killer (LAK) cells on the ascites formation and the survival time was examined using nude mice as a model, with malignant ascites produced by intraperitoneal inoculation of human ovarian cancer cells derived from ascites of a patient with serous cystadenocarcinoma of the ovary. Twenty-eight days after tumor inoculation, all nude mice in the untreated group and in the group treated with spleen cells alone formed ascites. Two of ten nude mice treated with IL-2 alone after tumor inoculation survived without forming ascites during the experimental period. On the other hand, all nude mice treated with LAK cells alone had formed ascites 14 days after tumor inoculation. When LAK cells and IL-2 were combined, five of ten mice survived without forming ascites during the experimental period. The survival time of the group treated with IL-2 alone was significantly prolonged compared to the groups that received medium alone, spleen cells alone and LAK cells alone. When administration of LAK cells was followed by IL-2, the survival time was further prolonged.Supported in part by a grant from the Special Scientific Research Program of the Defense Agency in Japan Offprini requests to: Y. Kikuchi     

热灌注基础上腹腔内贝伐珠单抗联合化疗治疗恶性腹水的临床观察

目的观察在热灌注的基础上腹腔内注射贝伐珠单抗(安维汀)联合腔内化疗治疗恶性腹水患者的疗效和安全性。方法 57例恶性腹水患者在热灌注的基础上随机分为腔内贝伐珠单抗联合化疗治疗组(治疗组)和腔内单纯化疗治疗组(对照组)。治疗前均先排尽腹水,以43～45.0℃灭菌0.9%生理盐水注入腹腔,持续有效循环40 min以上,排尽灌注液后治疗组在腹腔内注入贝伐珠单抗300 mg和氟尿嘧啶1 g。对照组除不加入贝伐珠单抗外,其余同治疗组。结果在可评价的57例患者中,治疗组总有效率为85.71%,对照组58.62%,P<0.05。全组患者耐受良好,无严重不良反应。结论热灌注基础上腹腔内贝伐珠单抗联合化疗治疗恶性腹水优于腔内单纯化疗且安全可靠。     

Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice

Summary The interleukin-2 (IL-2) mini-pellet, the carrier material of which is a biocompatible and biodegradable atelocollagen refined from bovine skin, contains 1×10⁶ units of IL-2 and can release IL-2 slowly in vivo by diffusion and dissolution. We have evaluated the antitumor effects of the IL-2 mini-pellet on an established solid murine tumor, methylcholanthrene-induced fibrosarcoma (Meth A). The subcutaneous administration of the IL-2 mini-pellet alone on days 8 and 11 after tumor inoculation significantly inhibited tumor growth. A significant inhibition was also seen when it was combined with the intravenous injection of 5×10⁷ lymphokine-activated killer (LAK) cells, in comparison to the untreated controls. Moreover, therapy with the IL-2 mini-pellet alone or in combination with LAK cells also prolonged the survival of mice bearing Meth A fibrosarcoma. In order to determine the precise mechanism of action of these antitumor effects, we tested splenocytes of treated mice for cytotoxic activity in vitro and investigated tumor tissues by an immunohistochemical method. On day 2 after the administration of the IL-2 mini-pellet, the lytic activity of splenocytes against both YAC-1 and JTC-11 cells (i.e. NK and LAK activity) was significantly augmented, and on day 7 a massive accumulation of lymphocytes, which were mainly like Thy1⁺ and/or asialo-GM1⁺ LAK cells, was seen in the tumor. These findings indicate that the IL-2 mini-pellet is an appropriate system for local administration of IL-2 and can induce LAK-like effector cells at the target site.Abbreviations used NK natural killer - IL-2 interleukin-2 - LAK lymphokine-activated killer - PBS phosphate-buffered saline     

The Effectiveness of the Treatment of Octreotide on Chylous Ascites After Liver Cirrhosis

Octreotide is a crucial drug used for treating patients with chylous ascites; however, there have been few reports related to octreotide that are being used in cirrhotic patients. Thus, this thesis is designed to determine the effects of octreotide on patients with chylous ascites after liver cirrhosis. Eight patients were diagnosed with chylous ascites, on the basis of laboratory findings on ascites samples, between January 2003 and May 2008. Octreotide was given to the six patients, while the remaining two were treated as a control. All patients had persistent peritonea drainage with the quantity and quality of the drainage fluid observed once every other day. All the necessary care was individually given to the patients during the therapy. All patients properly received combined therapy including a low-fat and low-sodium diet, and diuretic and peritoneal drainage. The volume of the peritoneal drainage was reduced to zero in one of the six patients who received octreotide therapy, while the other five had the drainage volumes decreased from 2,000 to 50 ml with a clear appearance and negative qualitative analysis of chyle. For those two patients who did not receive octreotide therapy, the conditions of peritoneal drainage seldom changed both from the qualitative and quantitative aspects. In conclusion, Octreotide, along with combined therapy, can rapidly relieve portal hypertension and reduce triglyceride levels in ascites. It appears to be an effective therapy available for the treatment of chylous ascites caused by liver cirrhosis.     

Experimental study on multidisciplinary treatment of pancreatic cancer

We investigated the antitumor effects of intratumoral (IT) injection of mitomycin-C (MMC), 5-fluorouracil (5FU), adriamycin (ADR), cisplatin (CDDP), streptozotocin (STZ), and interleukin-2 (IL-2) on well-differentiated pancreatic ductal adenocarcinoma (WD PaCa), a solid tumor model in the Syrian golden hamster. The growth of established palpable WD PaCa was not suppressed by intraperitoneal (IP) injection of these anticancer agents, whereas IT injection of MMC (1.0 mg/kg or more), 5FU (12.5 mg/kg or more), and CDDP (2.5 mg/kg or more) caused significant and marked suppression. The growth of established palpable WD PaCa was transiently suppressed by 50 Gy of local irradiation. The antitumor effect of irradiation was not enhanced by it injection of MMC before irradiation, whereas it was significantly enhanced by it injection after irradiation. Intraperitoneal injection of IL-2 (5 or 10 micrograms/d, 18 d) slightly suppressed the growth of established palpable tumors, but it injection of IL-2 caused significant and marked suppression, eliminating the tumor in 10-20% of the animals. Findings in this animal model of pancreatic cancer suggest that it treatment of anticancer agents or IL-2 might become an effective therapy for advanced pancreatic cancer.     

Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies

Autologous bone marrow transplantation (ABMT) for advanced hematologic malignancies is associated with high relapse rates. Interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells represent a potentially non-cross-resistant therapeutic modality that might prevent or delay relapses if used early after ABMT at a time when the tumor burden is minimal. However, high-dose chemoradiotherapy and ABMT might increase patients' susceptibility to IL-2 toxicity, and might interfere with immunologic responses to IL-2 in vivo. Therefore, to determine safety, tolerance, and immunomodulatory effects of IL-2 therapy early after ABMT, IL-2 was administered by continuous intravenous infusion to 16 patients 14 to 91 days (median, 33) after ABMT for acute leukemia, lymphoma, or multiple myeloma. Patients were sequentially assigned to escalating IL-2 "induction" doses (0.3 to 4.5 x 10(6) U/m2/d, days 1 to 5), and all patients received a nonescalating IL-2 "maintenance" dose (0.3 x 10(6) U/m2/d, days 12 to 21). Most patients exhibited mild to moderate fever, nausea, diarrhea, and/or skin rash with IL-2 infusions. The maximum tolerated "induction" dose was 3.0 x 10(6) U/m2/d; dose-limiting toxicities were hypotension and thrombocytopenia. All toxicities reversed on stopping the IL-2 infusions, and all patients completed "maintenance." Postinfusion lymphocytosis was exhibited by patients at all IL-2 dose levels. With the higher IL-2 doses, increased percentages of patients' PBMC expressed CD16 and CD56, with augmented lysis of K562 and Daudi, reflecting the induction of natural killer and circulating LAK effector activities. Increased LAK precursor activity was exhibited by patients at all IL-2 dose levels. Thus, the IL-2 therapy regimen was safely tolerated after ABMT, and pronounced immunomodulatory effects were observed with the higher IL-2 doses. These studies support the planned use of IL-2 and LAK cells after ABMT in an attempt to reduce relapses of advanced hematologic malignancies.     

腹水超滤浓缩回输腹腔术治疗肝硬化顽固性腹水疗效分析

目的 探讨腹水超滤浓缩回输腹腔术治疗肝硬化顽固性腹水的疗效。方法 将56例肝硬化顽固性腹水患者随机分为2组,均给予保肝、利尿及抗病毒治疗。在此基础上,对治疗组行腹水超滤浓缩回输腹腔术加小剂量人血白蛋白静脉滴注(静滴)(每滤出1000ml腹水,静滴人血白蛋白4g),对对照组行大量放腹水加大剂量人血白蛋白静滴(每抽出1000ml腹水,静滴人血白蛋白8g)。结果 术后第14天,治疗组患者24h尿量、血清ALB水平均高于对照组(P均<0.05),且治疗组总有效率高于对照组(P<0.05)。结论 腹水超滤浓缩回输腹腔术是一种安全有效的治疗肝硬化顽固性腹水的方法。     

Treatment of ascites

Opinion statement Ascites is the most common complication of cirrhosis and occurs in more than half of all patients with cirrhosis. The development of ascites indicates progression of the underlying cirrhosis and is associated with a 50% 2-year survival rate. Conventional therapies used for the treatment of ascites include sodium restriction (<88 mmol/d), diuretics, and large volume paracentesis (LVP) (>5 L). The most effective diuretic combination is that of a potassium-sparing, distal-acting diuretic (eg, spironolactone) with a loop diuretic (eg, furosemide). LVP provides rapid resolution of symptoms with minimal complications and is well tolerated by most patients. Post-paracentesis circulatory dysfunction (PPCD) may occur after LVP and is characterized by hyponatremia, azotemia, and an increase in plasma renin activity. PPCD is associated with an increased mortality and may be prevented by administration of albumin intravenously (6 to 8 g/L of ascites removed) along with LVP. The development of either diuretic-resistant or diuretic-intractable ascites occurs in approximately 5% to 10 % of all cases of ascites. This is a poor prognostic sign, as 50% of such patients die within 6 months of its development. The only definitive therapy for refractory ascites with cirrhosis is orthotopic liver transplantation. The other options that are available include LVP, peritoneovenous shunts, and transjugular intrahepatic portosystemic shunts (TIPS). The TIPS procedure has not been shown to have any influence on survival in patients with cirrhosis and refractory ascites, and TIPS is contraindicated in patients who have advanced liver failure because it can hasten death in such individuals. Peritoneovenous shunts are associated with a high incidence of complications and frequent occlusion. They are, therefore, rarely used for refractory ascites. Spontaneous bacterial peritonitis (SBP) is a common complication of cirrhotic ascites. It may precipitate hepatorenal syndrome. The overall mortality rate from an episode of SBP is approximately 20%. Following an episode of SBP, the 1-year mortality rate approaches 70%. Hospitalized patients should be treated with intravenous third-generation cephalosporins (eg, cefotaxime), and patients at risk should receive prophylaxis with either orally administered quinolones (eg, norfloxacin) or cotrimoxazole.     

Nonspecific cytotoxicity of recombinant interleukin-2 activated lymphocytes

The administration of interleukin-2 (IL-2) and lymphokine activated killer (LAK) cells to patients with advanced metastatic cancer has yielded encouraging results. The purported ability of LAK cells to be discriminatively tumoricidal, thus sparing normal host tissue, represents a major advance over conventional chemotherapy. However, IL-2 adoptive immunotherapy results in dose-limiting toxicity characterized by weight gain, dyspnea, ascites, and peripheral-pulmonary edema suggestive of a vascular leak syndrome. It is unclear whether the observed toxicity is directly related to IL-2 and/or LAK cells. The authors examined the cytolytic nature of human LAK cells against human endothelial, epithelial, and fibroblast cell lines. Bovine endothelial cells also were studied. Using a 51Cr release assay, the cytolytic potential, time course, and effect of reactive oxygen intermediate inhibitors were studied. LAK cells were uniformly toxic against all cell lines, in contrast to high dose rIL-2 and excipient. Significant cytolysis was observed within 30 minutes and increased over the first 2 hours of LAK cells coming in contact with target cells. Reactive oxygen intermediate inhibitors did not reduce cytolytic activity. The authors thus found human LAK cells to be rapidly cytolytic against a variety of human and bovine cell lines. This cytolysis was independent of reactive oxygen intermediates.     

重组IL2联合LAK和TIL细胞治疗癌性胸腔积液

采用自体淋巴因子激活的杀伤细胞(LAK)和重组白细胞介素2_rIL_2静脉滴注,同时将胸液中的肿瘤浸润淋巴细胞(TIL)体外培养、扩增后联同_rIL_2注入胸腔治疗肺癌癌性胸腔积液30例。结果显示完全缓解(CR)16例(53％),部分缓解(PR)12例(40％),无效(NC)2例(7％)。治疗后多数患者闷喘减轻,精神好转,食欲增加,体力增强,外周血白细胞增加,PR、NC病例胸液中淋巴细胞增多,癌胚抗原(CEA)下降。除12例(40％)出现一过性发热,4例(13％)出现荨麻疹,未作处理好转。表明本疗法治疗肺癌癌性胸腔积液是有效的,能提高患者的生存时间及生活质量。